A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Kelly, William Kevin
Hussain, Arif
Saraiya, Biren
Thanigaimani, Pradeep
Sun, Furong
Seebach, Frank A.
Lowy, Israel
Sandigursky, Sabina
Miller, Elizabeth
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA USA
[2] Univ Maryland, Med Ctr, Baltimore, MD USA
[3] Rutgers State Univ, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA
[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS284
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Rathkopf, Dana E.
    Picus, Joel
    Hussain, Arif
    Ellard, Susan
    Chi, Kim Nguyen
    Nydam, Thomas
    Allen-Freda, Erin
    Mishra, Kaushal Kishor
    Porro, Maria Grazia
    Scher, Howard I.
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 537 - 544
  • [42] Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    Powles, Thomas
    Yuen, Kobe C.
    Gillessen, Silke
    Kadel, Edward E.
    Rathkopf, Dana
    Matsubara, Nobuaki
    Drake, Charles G.
    Fizazi, Karim
    Piulats, Josep M.
    Wysocki, Piotr J.
    Buchschacher, Gary L., Jr.
    Alekseev, Boris
    Mellado, Begona
    Karaszewska, Boguslawa
    Doss, Jennifer F.
    Rasuo, Grozdana
    Datye, Asim
    Mariathasan, Sanjeev
    Williams, Patrick
    Sweeney, Christopher J.
    NATURE MEDICINE, 2022, 28 (01) : 144 - +
  • [43] Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    Thomas Powles
    Kobe C. Yuen
    Silke Gillessen
    Edward E. Kadel
    Dana Rathkopf
    Nobuaki Matsubara
    Charles G. Drake
    Karim Fizazi
    Josep M. Piulats
    Piotr J. Wysocki
    Gary L. Buchschacher
    Boris Alekseev
    Begoña Mellado
    Bogusława Karaszewska
    Jennifer F. Doss
    Grozdana Rasuo
    Asim Datye
    Sanjeev Mariathasan
    Patrick Williams
    Christopher J. Sweeney
    Nature Medicine, 2022, 28 : 144 - 153
  • [44] A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
    Dana E. Rathkopf
    Joel Picus
    Arif Hussain
    Susan Ellard
    Kim Nguyen Chi
    Thomas Nydam
    Erin Allen-Freda
    Kaushal Kishor Mishra
    Maria Grazia Porro
    Howard I. Scher
    George Wilding
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 537 - 544
  • [45] A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
    Dhawan, Mallika Sachdev
    Lee, Mina
    Bryce, Alan H.
    Weinberg, Vivian K.
    Ryan, Charles J.
    Derleth, Christina Louise
    Harzstark, Andrea Lynne
    Small, Eric Jay
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [46] Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer
    Fizazi, Karim S.
    Higano, Celestia S.
    Nelson, Joel B.
    Gleave, Martin
    Miller, Kurt
    Morris, Thomas
    Nathan, Faith E.
    McIntosh, Stuart
    Pemberton, Kristine
    Moul, Judd W.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1740 - +
  • [47] A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
    Laber, Damian A.
    Eatrides, Jennifer
    Jaglal, Michael V.
    Haider, Mintallah
    Visweshwar, Nathan
    Patel, Ankita
    MEDICAL ONCOLOGY, 2020, 37 (10)
  • [48] A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
    Yu, Evan Y.
    Nordquist, Luke
    Yazji, Salim
    Katz, Yisrael
    Coates, Elisabeth
    Vandross, Andrae Lavon
    Salkeni, Mohamad Adham
    Emamekhoo, Hamid
    Heath, Elisabeth I.
    De Kouchkovsky, Ivan
    Lang, Joshua Michael
    Nelson, Peter
    Breitmeyer, James Bradley
    Fong, Lawrence
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer.
    Yu, Evan Y.
    Yazji, Salim
    Katz, Yisrael
    Coates, Elisabeth
    Nordquist, Luke T.
    Vandross, Andrae Lavon
    Salkeni, Mohamad Adham
    Lang, Joshua Michael
    Nelson, Peter
    Breitmeyer, James Bradley
    Fong, Lawrence
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS241 - TPS241
  • [50] A phase I/II study of docetaxel in combination with pegylated liposomal doxorubicin in metastatic castration-resistant prostate cancer
    Damian A. Laber
    Jennifer Eatrides
    Michael V. Jaglal
    Mintallah Haider
    Nathan Visweshwar
    Ankita Patel
    Medical Oncology, 2020, 37
12345